Loading data for NVCT — first visit, this takes a few seconds.
Nuvectis Pharma, Inc.
22.72 -0.63 (-2.70%)
21.40 -2.37%
- Market Cap
- $715.6M
- Volume
- 3.87K
- Dividend yield
- n/a
- Next earnings date
- Nov 3, 2026
Nuvectis Pharma, Inc. (NVCT) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.30 | -$0.04 | 0.00% |
Metrics
- Bid
- 16.38
- Market Cap
- 716M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -30.3M
- -0.26
- -1.32
- n/a
- -22.83
- P/B (ttm)
- 64.47
- P/S (ttm)
- n/a
- Earnings Date
- Nov 3, 2026
- Ask
- 29.47
- Volume
- 3,873
- Avg. Volume (20D)
- 343,748
- Open
- 23.00
- Previous Close
- 23.35
- Day's Range
- 22.72 - 23.00
- 52-Week Range
- 5.55 - 29.27
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Nuvectis Pharma, Inc.
View profile →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2022
Employees 16
Stock Exchange NasdaqCM
Ticker Symbol NVCT
Website https://www.nuvectis.com